Antihypertensive medication prescribing in 27,822 elderly Canadians with diabetes over the past decade

Diabetes Care

Volumn 29, Issue 4, 2006, Pages 836-841

  McAlister, Finlay A ^a,b,f   Campbell, Norman R C ^c   Duong Hua, Minh ^b   Chen, Zhongliang ^b   Karen, T U ^b,d,e  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d TORONTO WESTERN HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; THIAZIDE DIURETIC AGENT;

AGED; ARTICLE; CANADA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DIET THERAPY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL SOCIETY; MONOTHERAPY; OUTCOME ASSESSMENT; PRESCRIPTION; TREATMENT DURATION;

EID: 33746333310     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.29.04.06.dc05-1875     Document Type: Article

References (26)

1. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570-2581, 2002
2. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291:335-342, 2004
3. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Venkat Narayan KM: A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 136:565-574, 2002
4. George PB, Tobin KJ, Corpus RA, Devlin WH, O'Neill WW: Treatment of cardiac risk factors in diabetic patients: how well do we follow the guidelines? Am Heart J 142:857-863, 2001
5. Borzecki AM, Wong AT, Hickey EC, Ash AS, Berlowitz DR: Hypertension control: how well are we doing? Arch Intern Med 163:2705-2711, 2003
6. Andrade SE, Gurwitz JH, Field TS, Kelleher M, Majumdar SR, Reed G, Black R: Hypertension management: the care gap between clinical guidelines and clinical practice. Am J Manag Care 10:481-486, 2004
7. Gulliford MC, Charlton J, Latinovic R: Trends in antihypertensive and lipid-lowering therapy in subjects with type 2 diabetes: clinical effectiveness or clinical discretion? J Hum Hypertens 19:111-117, 2005
8. McLean DL, Simpson SH, McAlister FA, Tsuyuki RT: Treatment to blood pressure targets in patients with diabetes: a systematic review. Can J Cardiol 20 (Suppl. D):93D, 2004
9. The CDC Diabetes Cost-effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542-2551, 2002
10. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study 33: intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853, 1998
11. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
12. Hux JE, Ivis F, Flintoft V, Bica A: Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25:512-516, 2002
13. Williams JI, Young W: A summary of studies on the quality of health care administrative databases in Canada. In Patterns of Health Care in Ontario: the ICES Practice Atlas. Goel V, Williams JI, Anderson GM, Blackstein-Hirsh P, Fooks C, Naylor CD, Eds. Ottawa, Ontario, Canada, Canadian Medical Association, 1996, p. 339-345
14. Tu K, Campbell NRC, Duong-Hua M, McAlister FA: Hypertension management in the elderly has improved: Ontario prescribing trends, 1994-2002. Hypertension 45:1113-1118, 2005
15. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 355:253-259, 2000
16. Ko DT, Mamdani M, Alter DA: Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 291:1864-1870, 2004
17. Schwartz JB: Gender-specific implications for cardiovascular medication use in the elderly. Cardiol Rev 11:275-298, 2003
18. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD: Persistence with treatment for hypertension in actual practice. CMAJ 160:31-37, 1999
19. Marentette MA, Gerth WC, Billings DK, Zarnke KB: Antihypertensive persistence and drug class. Can J Cardiol 18:649-656, 2002
20. Visser LE, Stricker BH, van der Elden J, Paes AHP, Bakker A: Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study. J Clin Epidemiol 48:851-857, 1995
21. Kostis JB, Shelton B, Gosselin G, Hood WB Jr, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW 3rd, Young JB, Probstfield J: Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). Am Heart J 131:350-55, 1996
22. Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S: Female preponderance for lisinopril-induced cough in hypertension. Am J Hypertens 7:1012-15, 1994
23. Shah MR, Granger CB, Bart BA, McMurray JJ, Petrie MC, Michelson EL, Swedberg K, Stevenson LW, Califf RM, Pfeffer MA: Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. Am J Med 109:489-492, 2000
24. Campbell NR, Onysko J, Maxwell C, Eliasziw M, Zhang JX: Increases in the diagnosis and drug treatment of hypertensive Canadians (Abstract). Can J Cardiol 21 (Suppl. C):67C, 2005
25. Joffres MR, Hamet P, Rabkin SW, Gelskey D, Hogan K, Fodor G: Prevalence, control and awareness of high blood pressure among Canadian adults: Canadian Heart Health Surveys Research Group. CMAJ 146:1997-2005, 1992
26. Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290:199-206, 2003